Research
Treating Tumors with Cixutumumab
IMC-A12 In Children with Relapsed or Refractory Solid Tumors
Protocol Description
This multi-center Phase II trial is studying IMC-A12, called cixutumumab, in treating young patients with solid tumors that have recurred or not responded to treatment. Researchers will study how the body processes the drugs, potential side effects and benefits.
Eligibility Criteria
Subject to certain screening requirements, this study is enrolling patients of both genders up to age 30, who have a solid tumor that has come back after treatment or not responded to treatment.
Boys: All ages
Girls: All ages
Requirements
Participating children will receive intravenous doses of cixutumumab over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Frequency of visits: Weekly
Duration: About 22 months
Status: Open for Enrollment
Sources of Support
Children’s Oncology Group
National Cancer Institute
Additional Resources
Study Description at National Institutes of Health
Primary Investigator(s)
Regina Jakacki, MD
Contact Information
To get started, please contact:
Sharon DiBridge, CRA
412-692-7070
Angela Krol, Research RN, BSN
412-692-8047
